Loading...
•
Dec 31, 2019
Merus Q4 2019 Earnings Report
Merus reported financial results for Q4 and full year 2019 and provided a business update.
Key Takeaways
Merus N.V. announced financial results for the fourth quarter and full year ended December 31, 2019. The company's cash, cash equivalents and marketable securities totaled $241.8 million at the end of 2019, and the company expects to be funded into 2022.
Encouraging, early clinical activity in zenocutuzumab program for NRG1+ cancers.
Phase 1/2 eNRGy trial enrollment continues for NRG1+ cancers.
Phase 2 interim analysis reported for metastatic breast cancer trial.
Cash runway extended, Merus expects to be funded into 2022 through first follow-on offering.
Merus
Merus
Forward Guidance
Based on the Company’s current operating plan, the Company expects its existing cash, cash equivalents and investments will be sufficient to fund its operations into 2022.